研究業績 2017年

  • Hashimoto H, Saito M, Kanda N, Yamamoto T, Mieno M, Hatakeyama S. Dose-dependent effect of daptomycin on the artificial prolongation of prothrombin time in coagulation abnormalities: in vitro verification. BMC Pharmacol Toxicol. 2017 18(1):74. [open access]
  • Higashino T, Takada T, Nakaoka H, Toyoda Y, Stiburkova B, Miyata H, Ikebuchi Y, Nakashima H, Shimizu S, Kawaguchi M, Sakiyama M, Nakayama A, Akashi A, Tanahashi Y, Kawamura Y, Nakamura T, Wakai K, Okada R, Yamamoto K, Hosomichi K, Hosoya T, Ichida K, Ooyama H, Suzuki H, Inoue I, Merriman TR, Shinomiya N, Matsuo H. Multiple common and rare variants of ABCG2 cause gout. RMD Open 2017 3:e000464. [open access]
  • Ogawa M, Yamanashi Y, Takada T, Abe K, Kobayashi S. Effect of luteolin on the expression of intestinal cholesterol transporters. J Funct Foods 2017 36:274-279. [abstract]
  • Yamamoto T, Furihata K, Hisaka A, Moritoyo T, Ogoe K, Kusayama S, Motohashi K, Mori A, Iwatsubo T, Suzuki H. Notable Drug–Drug Interaction Between Etizolam and Itraconazole in Poor Metabolizers of Cytochrome P450 2C19. J Clin Pharmacol. 2017 57(11):1491-1499. [abstract]
  • Toyoda Y, Takada T, Suzuki H. Spontaneous production of glutathione-conjugated forms of 1,2-dichloropropane: comparative study on metabolic activation processes of dihaloalkanes associated with occupational cholangiocarcinoma. Oxid Med Cell Longev. 2017 2017:9736836. [open access]
  • Ando H, Hatakeyama H, Sato H, Hisaka A, Suzuki H. Determinants of intestinal availability for P-glycoprotein substrate drugs estimated by extensive simulation with mathematical absorption models. J Pharm Sci. 2017 106(9):2771-2779. [abstract]
  • Oriyama T, Yamamoto T, Yanagihara Y, Nara K, Abe T, Nakajima K, Aoyama T, Suzuki H. Evaluation of the permeation of antineoplastic agents through medical gloves of varying materials and thickness and with varying surface treatments. J Pharm Health Care Sci. 2017 3:13. [open access]
  • Saito M, Hatakeyama S, Hashimoto H, Suzuki T, Jubishi D, Kaneko M, Kume Y, Yamamoto T, Suzuki H, Yotsuyanagi H. Dose-dependent artificial prolongation of prothrombin time by interaction between daptomycin and test reagents in patients receiving warfarin: a prospective in vivo clinical study. Ann Clin Microbiol Antimicrob. 2017 16(1):27. [abstract]
  • Yamamoto H, Takada T, Yamanashi Y, Ogura M, Masuo Y, harada-Shiba M, Suzuki H. VLDL/LDL acts as a drug carrier and regulates the transport and metabolism of drugs in the body. Sci Rep. 2017 7:633. [open access] [プレスリリース] [本論文の内容がNewton（2017年7月号12ページ）で紹介されました]
  • Toyoda Y, Takada T, Gomi T, Nakagawa H, Ishikawa T, Suzuki H. Clinical and Molecular Evidence of ABCC11 Protein Expression in Axillary Apocrine Glands of Patients with Axillary Osmidrosis. Int J Mol Sci. 2017 18(2):417. [open access]
  • Yamanashi Y, Takada T, Kurauchi R, Tanaka Y, Komine T, Suzuki H. Transporters for the Intestinal Absorption of Cholesterol, Vitamin E, and Vitamin K. J Atheroscler Thromb. 2017 24(4):347-359. [abstract]
  • Nakayama A, Nakaoka H, Yamamoto K, Sakiyama M, Shaukat A, Toyoda Y, Okada Y, Kamatani Y, Nakamura T, Takada T, Inoue K, Yasujima T, Yuasa H, Shirahama Y, Nakashima H, Shimizu S, Higashino T, Kawamura Y, Ogata H, Kawaguchi M, Ohkawa Y, Danjoh I, Tokumasu A, Ooyama K, Ito T, Kondo T, Wakai K, Stiburkova B, Pavelka K, Stamp LK, Dalbeth N, Eurogout Consortium, Sakurai Y, Suzuki H, Hosoyamada M, Fujimori S, Yokoo T, Hosoya T, Inoue I, Takahashi A, Kubo M, Ooyama H, Shimizu T, Ichida K, Shinomiya N, Merriman TR, Matsuo H. GWAS of clinically-defined gout and subtypes identifies multiple susceptibility loci including urate transporter genes. Ann Rheum Dis. 2017 76:869-877. [open access]
  • Book chapter
    Yamanashi Y, Takada T, Suzuki H. Bile Acid as Therapeutic Agents. in; Tazuma S and Takikawa H (Eds.) Bile Acids in Gastroenterology Basic and Clinical Springer Japan, 2017 61-90.